Pharmathen has developed one of the most advanced pipelines of long-acting injectables, sustained-release oral solids, and ophthalmic formulations, produced in its US-FDA and EU-approved manufacturing facilities in Greece. The acquisition serves to reinforce Pharmathen’s position in the global peptide therapeutics market, currently estimated at EUR 38 billion.
CBL Patras is one of the key peptide material suppliers in Europe. Established in 1990 by Professor Dr. Kleomenis Barlos, the Barlos family will continue to work closely with Pharmathen and CBL, to solidify the integrated businesses on a global scale and accommodate necessary expansion.
Caroline Notté, NautaDutilh’s Corporate M&A partner who led the deal, commented: "Assisting Pharmathen on this acquisition, alongside the London team of Ropes & Gray, was a rewarding experience. The NautaDutilh team was happy to participate in this transaction which opens doors for Pharmathen to broaden its product range for customers and, importantly, enhances access to affordable medicines.”
The team further consisted of senior associate Brice Bertolotti and associates Armin Klüter and Antonio Marin from our Corporate M&A practice.